Factors influencing clinical outcomes of acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator

被引:21
|
作者
Huang Yin-hui [1 ]
Zhuo Shi-tu [2 ]
Chen Ya-fang [2 ]
Li Ming-mei [3 ]
Lin You-yu [1 ]
Yang Mei-li [2 ]
Chen Zhen-jie [3 ]
Cai Ruo-wei [2 ]
机构
[1] Hosp Jinjiang City, Dept Neurol, Jinjiang 362000, Fujian, Peoples R China
[2] Fujian Med Univ, Affiliated Hosp 2, Dept Neurol, Quanzhou 362000, Fujian, Peoples R China
[3] Mingxuan Hosp Anxi Cty, Dept Neurol, Anxi 362000, Fujian, Peoples R China
关键词
recombinant tissue plasminogen activator; introvenous thrombolysis; acute ischemic stroke; outcome; BLOOD-PRESSURE PROFILES; INDUCED RECANALIZATION; SAFE IMPLEMENTATION; POOLED ANALYSIS; RT-PA; THROMBOLYSIS; PREDICTORS; ASSOCIATION; MANAGEMENT; ECASS;
D O I
10.3760/cma.j.issn.0366-6999.20132354
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Thrombolysis with recombinant tissue plasminogen activator (rt-PA) has gained international recognition, clinical outcomes following this thrombolytic therapy varied from patient to patient. Factors affecting clinical outcomes have not been well understood yet, so this retrospective case-control study aimed to investigate factors that may influence clinical outcomes of acute ischemic stroke treated with intravenous rt-PA. Methods One hundred and one patients with acute ischemic stroke who received intravenous rt-PA thrombolysis within 4.5 hours from disease onset were included. Patients were divided into good or poor outcome group according to modified Rankin Scale (mRS) score, good outcome group: mRS score of 0-1; poor outcome group: mRS of 2-6. Stroke characteristics were compared between the two groups. Factors for stroke outcomes were analyzed via univariate analysis and Logistic regression. Results Of the 101 patients studied, patients in good outcome group (n=55) were significantly younger than patients in poor outcome group (n=46, (62.82 +/- 14.25) vs. (68.81 +/- 9.85) years, P=0.029). Good outcome group had fewer patients with diabetic history (9.09% vs. 28.26%, P=0.012), fewer patients with leukoaraiosis (7.27% vs. 28.26%, P=0.005) and presented with lower blood glucose level ((5.72 +/- 1.76) vs. (6.72 +/- 1.32) nnmol/L, P=0.012), lower systolic blood pressure level ((135.45 +/- 19.36) vs. (148.78 +/- 19.39) mmHg, P=0.003), lower baseline NIHSS score (12.02 +/- 5.26 vs. 15.78 +/- 4.98, P=0.002) and shorter onset-to-treatment time (OTT) ((2.38 +/- 1.21) vs. (2.57 +/- 1.03) hours, P=0.044) than poor outcome group. Logistic regression analysis showed that absence of diabetic history (odds ratio (OR) 0.968 (95% CI 0.941-0.996)), absence of leukoaraiosis (OR 0.835 (95% CI 0.712-0.980)), lower baseline NIHSS score (OR 0.885 (95% CI 0.793-0.989)), lower pre-thrombolysis systolic blood pressure (OR 0.962 (95% CI 0.929-0.997)), and lower blood glucose level (OR 0.699 (95% CI 0.491-0.994)) before thrombolysis were significantly associated with better outcome. Conclusion Patients with no history of diabetes, no leukoaraiosis, low blood glucose level, low systolic blood pressure level and low baseline NIHSS score before thrombolysis have a better outcome.
引用
收藏
页码:4685 / 4690
页数:6
相关论文
共 50 条
  • [1] Factors influencing clinical outcomes of acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator
    HUANG Yin-hui
    ZHUO Shi-tu
    CHEN Ya-fang
    LI Ming-mei
    LIN You-yu
    YANG Mei-li
    CHEN Zhen-jie
    CAI Ruo-wei
    [J]. 中华医学杂志(英文版), 2013, 126 (24) : 4685 - 4690
  • [2] Quantitative electroencephalograph in acute ischemic stroke treated with intravenous recombinant tissue plasminogen activator
    Yang, Juan
    Zhao, Xiaohui
    Bai, Qingke
    Zhao, Zhengguo
    Sui, Haijing
    [J]. INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2017, 10 (01): : 507 - 514
  • [3] Update on Intravenous Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke
    Fugate, Jennifer E.
    Rabinstein, Alejandro A.
    [J]. MAYO CLINIC PROCEEDINGS, 2014, 89 (07) : 960 - 972
  • [4] The use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke
    Kahn, JH
    Viereck, J
    Kase, C
    Jeerakathil, T
    Romero, R
    Mehta, SD
    Kociol, R
    Babikian, V
    [J]. JOURNAL OF EMERGENCY MEDICINE, 2005, 29 (03): : 273 - 277
  • [5] Intravenous thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke in a patient treated with rivaroxaban
    van Hooff, Robbert-Jan
    Nieboer, Koenraad
    De Smedt, Ann
    Yperzeele, Laetitia
    Jochmans, Kristin
    De Keyser, Jacques
    Brouns, Raf
    [J]. CLINICAL NEUROLOGY AND NEUROSURGERY, 2014, 122 : 133 - 134
  • [6] Real-World Outcomes of Acute Ischemic Stroke Treatment with Intravenous Recombinant Tissue Plasminogen Activator
    Betts, Keith A.
    Hurley, Dana
    Song, Jinlin
    Sajeev, Gautam
    Guo, Jenny
    Du, Ella Xiaoyan
    Paschoalin, Marco
    Wu, Eric Q.
    [J]. JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2017, 26 (09): : 1996 - 2003
  • [7] Racial and Ethnic Disparities in the Use of Intravenous Recombinant Tissue Plasminogen Activator and Outcomes for Acute Ischemic Stroke
    Nasr, Deena M.
    Brinjikji, Waleed
    Cloft, Harry J.
    Rabinstein, Alejandro A.
    [J]. JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2013, 22 (02): : 154 - 160
  • [8] Recombinant tissue plasminogen activator for acute ischemic stroke
    Al-Buhairi, AR
    Jan, MM
    [J]. SAUDI MEDICAL JOURNAL, 2002, 23 (01) : 13 - 19
  • [9] Factors influencing functional outcome after intravenous thrombolysis with tissue plasminogen activator in acute ischemic stroke
    Mendizabal, JE
    Shah, AK
    Zweifler, RM
    [J]. ANNALS OF NEUROLOGY, 2000, 48 (03) : 500 - 501
  • [10] Acute Ischemic Stroke in Term Pregnancy Treated with Recombinant Tissue Plasminogen Activator
    Aaron, Sanjith
    Mannam, Pavitra Ratna
    Shaikh, Atif
    Mani, Arun Mathai
    Bal, Deepti
    Pandian, Jeyaraj Durai
    [J]. CASE REPORTS IN NEUROLOGY, 2020, 12 (SUPPL 1) : 4 - 8